Physician profile
Daniel E Font Rivera
NPI 1669029377
$6,776.06
in general payments reported to CMS, 2019-2025
29 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what 79% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $16.74 · 2021: $584 · 2022: $1,258 · 2023: $1,622 · 2024: $1,980 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,382 · Education: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,381.55 |
| Education | $329.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,516.91 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $717.14 | 2022-2025 | Ofev |
| Janssen Pharmaceuticals, INC | $655.08 | 2019-2025 | Xarelto, Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $428.44 | 2022-2023 | Nucala, Arexvy, Trelegy Ellipta |
| United Therapeutics Corporation | $394.32 | 2023-2025 | Tyvaso, Steen Solution, Tyvaso |
| E.R. Squibb & Sons, L.L.C. | $378.31 | 2021-2025 | Eliquis, Opdivo |
| Merck Sharp & Dohme LLC | $261.83 | 2022-2025 | Capvaxive, Winrevair, Verquvo |
| Genzyme Corporation | $242.18 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $237.87 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $231.53 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $230.98 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $210.69 | 2022-2024 | Uptravi, Opsumit |
| Boston Scientific Corporation | $209.84 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $167.43 | 2022-2025 | Glassia |
| Insmed, INC. | $126.80 | 2023-2024 | Arikayce |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $103.68 | 2021-2024 | Yupelri |
| Tempus Ai, INC | $100.00 | 2024 | |
| Pbg Puerto Rico LLC | $78.41 | 2021-2024 | |
| Amgen INC. | $77.62 | 2024 | Tezspire |
| Chiesi USA, INC. | $70.65 | 2021-2025 | Cleviprex |
| Jazz Pharmaceuticals INC. | $69.95 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $55.97 | 2022 | |
| Pfizer INC. | $51.58 | 2023 | |
| Mallinckrodt Hospital Products INC. | $37.50 | 2023 | Acthar |
| Deciphera Pharmaceuticals INC. | $25.00 | 2022 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $25.00 | 2025 | Zepbound |
| Ani Pharmaceuticals, INC. | $25.00 | 2023 | Purified Cortrophin Gel |
| Abbvie INC. | $24.95 | 2022 | |
| Genentech USA, INC. | $21.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Font Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.